XNAS · Healthcare · Biotechnology
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.80 | -0.99 | -23.75% | $696,000 | ❌ Miss | -8.36% | +0.60% | — |
| 2026-03-04 | Q4 2025 | -0.76 | -0.81 | -6.58% | $620,000 | ❌ Miss | +0.16% | -17.11% | -25.56% |
| 2025-11-05 |
| Q3 2025 |
| -0.77 |
| -0.85 |
| -10.39% |
| $966,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -0.75 | -0.85 | -13.33% | $5.3M | ❌ Miss | -0.83% | +4.06% | +32.42% |
| 2025-03-05 | Q4 2024 | -0.48 | -0.64 | -33.33% | $11.6M | ❌ Miss | +3.65% | +11.40% | -29.94% |
| 2024-11-07 | Q3 2024 | -0.55 | -0.54 | +1.82% | $10.5M | ✅ Beat | +0.35% | -9.49% | -23.64% |
| 2024-08-07 | Q2 2024 | -0.52 | -0.58 | -11.54% | $9.5M | ❌ Miss | +5.90% | -12.37% | -7.86% |
| 2024-05-08 | Q1 2024 | -0.42 | -0.55 | -30.95% | $11.7M | ❌ Miss | +9.60% | +11.94% | -21.28% |
Showing last 8 quarters.